{"nctId":"NCT02175277","briefTitle":"Darbepoetin Alfa MDS Companion Protocol","startDateStruct":{"date":"2014-06-12","type":"ACTUAL"},"conditions":["Myelodysplastic Syndrome (MDS)"],"count":9,"armGroups":[{"label":"Darbepoetin Alfa","type":"EXPERIMENTAL","interventionNames":["Drug: Darbepoetin Alfa"]}],"interventions":[{"name":"Darbepoetin Alfa","otherNames":["Aranesp®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/ procedures being initiated;\n* Subject must continue long term follow up within parent study (20090160);\n* Subject must have an ongoing clinically relevant erythroid response as assessed by the Investigator using current response criteria (ie, International Working Group (IWG) response criteria);\n\nExclusion Criteria:\n\n* Transfusion dependence defined as receiving a total of ≥ 4 units of red blood cell (RBC) transfusion in the previous 8-week period prior to enrolment;\n* Known diagnosis of acute myelogenous leukemia (AML) or marrow collagen fibrosis;\n* Known refractory anaemia with excess blast-2 (RAEB-2);\n* Known diagnosis of intermediate-2 or high risk MDS per International Prognostic Scoring System (IPSS);\n* Subjects received thrombopoiesis-stimulating factors (eg, eltrombopag, romiplostim) in the MDS 20090160 study or planning to receive such agents during the study;\n* Other protocol defined inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events","description":"Adverse events (AEs) were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, where Grade 1 indicates a mild AE, Grade 2 indicates a moderate AE, Grade 3 indicates severe or medically significant but not immediately life-threatening and Grade 4 indicates life-threatening consequences; urgent intervention indicated.\n\nA serious adverse event was defined as an adverse event that met at least one of the following serious criteria:\n\n* fatal\n* life threatening\n* required in-patient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event The investigator assessed whether each adverse events was related to darbepoetin alfa.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":9},"commonTop":["Fatigue","Dyspnoea exertional","Abdominal discomfort","Cough","Oropharyngeal pain"]}}}